Cancers, Vol. 12, Pages 221: Precision Medicine in Soft Tissue Sarcoma Treatment

Cancers, Vol. 12, Pages 221: Precision Medicine in Soft Tissue Sarcoma Treatment Cancers doi: 10.3390/cancers12010221 Authors: Nakano Takahashi Soft tissue sarcoma (STS) is a rare component of malignant diseases. STS includes various histological subtypes, and there are some important differences among the different histological subtypes regarding the mutation profile and sensitivity to antitumor agents. Many clinical trials of STS incorporating many different histological subtypes in various populations have been conducted; it is difficult to compare the findings and make conclusions about clinical efficacy. Targeted therapies focusing on specific histological subtypes and precision therapy focusing on the specific genetic mutation(s) of each STS patient are being investigated. Since STS patients are a small population, new clinical trial designs are required to evaluate and establish new targeted therapies for each histological subtype that has a limited number of patients, and preclinical investigations are needed to detect targetable mutations. Now that cancer genome profiling is used in clinical practice, it is urgently necessary to connect the genome profiling data obtained in clinical settings to the optimal clinical treatment strategies. Herein we review the development and challenges of precision therapy in the management of STS patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research